Currently, a few drugs are undergoing early-phase clinical trials on relapsed/refractory AML patients with KMT2Ar/NPM1 to evaluate efficacy as either an MLL-Menin complex inhibitor (KO-539 (NCT04067336), SNDX-5613 (NCT04065399), and JNJ-75276617 (NCT04811560)) or menin inhibitor (DS-1594b (NCT04752163) and BMF-219 (NCT05153330)). Here, KMT2A is linked to acute myeloid leukemia.